Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 494

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 494
---
 of Regulation S -Xunder Securities Act of 1933, as amended. The application of the acquisition method of accounting is dependent upon certain valuations and other studies that have yet to be completed. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial statements. Differences between these preliminary estimates and the final acquisition accounting may occur and these differences could have a material impact on the 266 accompanying unaudited pro forma condensed combined financial statements and the combined company’s future results of operations and financial position. The actual amounts recorded as of the completion of the Merger may differ materially from the information presented in these unaudited pro forma condensed combined financial statements. The unaudited pro forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that would have been realized had Kadimastem and NLS been a combined company during the specified period. The unaudited pro forma adjustments represent NLS’s best estimates based on currently available information and assumptions management believes are reasonable, as described in the accompanying notes. In summary, the unaudited pro forma condensed combined financial statements reflect the following adjustments: (1) the recognition of cash proceeds from capital investments; (2) payments for transaction -relatedcosts; (3) the conversion of the convertible component of Kadimastem’s loan and the exercise of warrants, resulting in an increase to the cash balance; (4) the recording of goodwill as part of the Merger transaction; (5) the conversion of related -partyloans by Kadimastem into equity; and (5) the adjustment to reflect NLS par value of CHF 0.03 from CHF 0.80 and (6) the elimination of Kadimastem’s share capital and share premium, and NLS’s accumulated deficit in connection with the reverse triangular merger, as Kadimastem will be the surviving operating entity for accounting purposes. 267

Unaudited Pro Forma Condensed Combined Balance Sheets

|                                                                                           |     | December 31, 2024 |            |     |               |